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Abstract
Background
Only a small fraction of HIV-1-infected patients develop broadly neutralizing antibodies
(bNAbs), a process generally associated to chronic antigen stimulation. It has been
described that rare aviremic HIV-1-infected patients can generate bNAbs but this issue
remains controversial. To address this matter we have assessed bNAb responses in a large
cohort of long-term non-progressors (LTNPs) with low or undetectable viremia.
Methods
Samples from the LTNP cohort of the Spanish AIDS Research Network (87 elite and 42
viremic controllers) and a control population of 176 viremic typical-progressors (TPs) were
screened for bNAbs using Env-recombinant viruses. bNAb specificities were studied by
ELISA using mutated gp120, neutralization assays with mutated viruses, and peptide com-
petition. Epitope specificities were also elucidated from the serum pattern of neutralization
against a panel of diverse HIV-1 isolates.
Results
Broadly neutralizing sera were found among 9.3% LTNPs, both elite (7%) and viremic
controllers (14%). Within the broadly neutralizing sera, CD4 binding site antibodies were
detected by ELISA in 4/12 LTNPs (33%), and 16/33 of TPs (48%). Anti-MPER antibodies
were detected in 6/12 LTNPs (50%) and 14/33 TPs (42%) whereas glycan-dependent HIV-
1 bNAbs were more frequent in LTNPs (11/12, 92%) as compared to TPs (12/33, 36%). A
good concordance between standard serum mapping and neutralization-based mapping
was observed.
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Conclusion
LTNPs, both viremic and elite controllers, showed broad humoral immune responses
against HIV-1, including activity against many major epitopes involved in bNAbs-mediated
protection.
Introduction
Production of broadly neutralizing antibodies (bNAbs) against HIV represents a relatively
infrequent event in HIV-infected patients [1,2]. One major issue to induce such antibodies
resides in the high variability of the viral envelope and structural mechanisms hiding crucial
epitopes for neutralization. Besides, maturation leading to high affinity antibodies represents a
major challenge for the immune system that can be impaired by the immunodeficiency associ-
ated with HIV infection. Affinity maturation of antibodies is critical to confer effective neutral-
ization against HIV and this maturation capacity becomes altered along infection [3–5].
Despite the complexity of such mechanisms of viral escape, some antibodies are able to
overcome these barriers and display a broad neutralizing activity. These bNAbs are mainly
directed to four vulnerable Env regions: the gp120 CD4-binding site (CD4bs) [6–10], the gp41
membrane proximal external region (MPER) [11–13], glycan-dependent epitopes in the sec-
ond hypervariable loop (V2) [14–16] and glycan dependent epitopes around the third hyper-
variable loop (V3) [11,15]. In addition these four well-established sites, new epitopes at the
gp120-gp41 interface recognized by some more recently discovered bNAbs have been identi-
fied [17–20].
The study of the mechanism of action of bNAbs is essential to understand the mechanisms of
antibody neutralization and escape by HIV-1. Several studies have suggested that the develop-
ment of neutralizing antibodies is a consequence of viral replication [1,21]. On the other hand, it
is generally accepted that bNAbs are not able to contribute the control of viremia due to contin-
uous escape by HIV from immune pressure through mutation or glycosylation. However, it has
been recently described a role of bNAbs in HIV control in one patient with EC phenotype rais-
ing the possibility of an active role of bNAbs in the control of autologous viruses [22].
We have shown that patients receiving antiretroviral treatment are capable of inducing a
broad and potent humoral immune response against HIV despite having undetectable levels
of viremia [23]. According to these results, it is possible that long-term nonprogressors
(LTNPs), individuals with low levels of viremia who maintain stable CD4 T cell counts over 10
years of infection, develop neutralizing antibodies with a high affinity profile. In fact, in iso-
lated LTNP patients the presence of bNAbs has been described [24–26]. We have explored the
hypothesis that preserved B cell function in LTNPs could result in the production of a broad
humoral response. To get a better understanding of this issue, we have assessed the presence of
bNAbs in a large cohort of LTNP, including both viremic and elite controllers. Furthermore
we have characterized the epitopes targeted by bNAbs found in LTNPs in comparison with
those in HIV typical progressors (TPs).
Material and methods
HIV-1 infected subjects
This study has been approved by Research Ethics and Animal Welfare Committee of Instituto
de Salud Carlos III (CEI PI 42_2011-v2).
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Samples (129) from the cohort of LTNPs from the RIS (median RNA copies/ml: 104,
median CD4+: 734 cells/μl and asymptomatic HIV infection over 10 year after seroconversion)
were kindly provided by the HIV BioBank integrated in the Spanish AIDS Research Network
(RIS) [27]. The HIV BioBank, integrated in the Spanish AIDS Research Network, is partially
funded by the RD12/0017/0037 project as part of the Plan Nacional R + D + I and cofinanced
by ISCIII- Subdirección General de Evaluación y el Fondo Europeo de Desarrollo Regional
(FEDER) and Fundación para la investigación y prevención del SIDA en España (FIPSE).
Samples were processed following current procedures and frozen immediately after their
reception. All patients participating in the study gave their informed consent and protocols
were approved by institutional ethical committees. A population of 176 untreated TPs (median
RNA copies/ml: 10,241, median CD4+: 567 cells/μl) from Hospital Clinic, Barcelona, was ana-
lyzed as control [23]. The overall rate of CD4 cell decline in TPs was 50–100 cells/μL per year.
Patients in the present study signed informed consent. All subjects on this study were antire-
troviral naïve at the time of sampling.
LTNPs were classified as elite and viremic controllers (Table 1). Among LTNPs, 87 of them
were elite controllers with persistent viral load below 50 RNA copies/ml and a median CD4+ T
cell count of 773 cells/μl and 42 were viremic controllers. Viremic controllers had a median
number of viral RNA copies/ml in plasma of 3,450, a median CD4+ T cell count of 655 cells/μl
and viral load was always below 10000 RNA copies/ml.
HIV-1 neutralization assays
To evaluate neutralizing antibody titers against HIV-1, Env-reporter viruses carrying a Renilla
luciferase gene in nef were generated by cloning the full-length envelope in the pNL–lacZ/env–
Ren vector, as previously described [28]. VI191 (A), NL4-3 (B), 92BR025 (C), 92UG024 (D),
CM244 (AE) and NP1525 (CRF01_AE) envelopes were amplified from culture supernatants
kindly provided by Dr. H. Holmes (NIBSC, UK) through the NeutNet consortium (Dr. G.
Scarlatti) [29]. Envelopes from strains X-845-4 (F1), X-1628-2 (G), P-1261 (CRF02_AG) and
2105 (CRF14BG/B) were amplified from culture supernatants kindly provided by Dr. Lucı́a
Pérez Álvarez, Instituto de Salud Carlos III, Spain [30]. Samples for the amplification of sub-
type B chronic and acute envelopes (14382, 37343, 325 and 29) were provided by Dr. José
Marı́a Miró from Hospital Clinic, Barcelona. The viruses chosen represent different HIV-1
subtypes, varying neutralization sensitivity and coreceptor usage (Table 2). An amphotropic
vesicular stomatitis virus (VSV) Env pseudotyped HIV-1 was added to the panel as a specificity
control virus in neutralization testing.
Infectious supernatants were generated by calcium phosphate transfection in HEK 293 T
cells with 5 μg of the plasmids [31]. Titrated recombinant viruses were preincubated with the
dilutions of sera (1/200-1/2000) for 30 minutes at 37˚C before the infection of the U87.CD4.
Table 1. Clinical data and neutralization screening results for the patient groups.
LTNPs Typical progressors
Elite controllers Viremic controllers
No. of sera 87 42 176
Viral RNA copies/ml plasma (median) <50 3,450 10,241
No. of CD4+ T cells/μl (median) 773 655 567
Years since diagnosis (median/range) 17.3 (10–25) 14.8 (10–26) 5 (0–24)
Broadly neutralizing sera 6/87 (7%) 6/42 (14%) 33/176 (19%)
 In some old samples (n = 34) the threshold of detection was <500 RNA copies/ml
https://doi.org/10.1371/journal.pone.0193773.t001
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CCR5 or U87.CD4.CXCR4 cells (2x104 per well) [32]. Virus infectivity was determined 48 h
postinoculation by measuring luciferase activity in cell lysates using a 96-well plate lumin-
ometer (Orion, Berthold). Sigmoid curves were generated and ID50 neutralization titers were
calculated by non-linear regression using GraphPad Prism version 7.02 software. In a first
screening, serum samples were tested with a minipanel of four recombinant viruses with enve-
lopes from different subtypes and tropisms and a VSV-pseudotyped virus. Selected serum
samples neutralizing all the viruses in the minipanel with an ID50200 were screened against
a panel of 10 more viruses.
Epitope mapping
i. Neutralization assays. For the characterization of neutralizing antibodies, neutraliza-
tion assays were performed using single-round infection HIV-1 Env pseudoviruses and
TZM-bl target cells as previously described [33,34]. To determine the serum concentration
producing 50% reduction in RLU value, serial dilutions were made and the neutralization
dose-response curves were fitted by non-linear regression using a four-parameter hill slope
equation.
For the assessment of CD4bs-directed neutralization, antibody-mediated neutralization
was blocked with specific protein probes in a competition assay [7]. Briefly, 25 μg/ml of RSC3
(Resurfaced Stabilized Core 3) or 25 μg/ml of the mutant RSC3 Δ371I/P363N was incubated
with sera serially diluted 4-fold starting from 1:10 for 30 min. JR-FL (subtype B), RW020 (sub-
type A) or ZA012 (subtype C) pseudovirus was added 30 min before the addition of TZM-bl
cells and the infection proceeded for 48 h. CD4bs-directed activity was calculated as a 30%
reduction in the ID50 values of the sera in the presence of RSC3 compared to RSC3 Δ371I/
P363N [35].
For the mapping of bNAbs directed to glycan structures in the variable region (V1V2 and
V3), neutralization assays in TZM-bl were performed using JR-CSF virus with the N160K
mutation and the N332A mutation respectively [36,37]. The mutation of N160 to lysine, an N-
glycosylation site in the V2 loop, abolishes the neutralization mediated by PG9 and PG16 and
N332A mutation removes a glycosylation site at the base of V3 loop essential for the formation
Table 2. Characteristics of the viruses used in the neutralization assays.
SUBTYPE VIRUS CODE CORECEPTOR USAGE INFECTION STAGE TIER
A VI191 R5 Chronic 2
B NL4-3 X4 Chronic 1A
B 14382 R5 Acute n.d.
B 37313 R5 Acute n.d.
B 325 X4 Chronic n.d.
B 29 R5X4 Chronic n.d.
C 92BR025 R5 Chronic 1B
D 92UG024 X4 Chronic 2
AE CM244 R5 Chronic 2
F1 845_4 R5 Chronic n.d.
G 1628_2 R5 Chronic n.d.
CRF02_AG 1261 R5X4 Chronic n.d.
CRF14_BG/B 2105 R5 Chronic n.d.
CRF01_AE NP1525 X4 Chronic n.d.
 Recombinant viruses included in the mini-panel
https://doi.org/10.1371/journal.pone.0193773.t002
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of epitopes recognized by 2G12 and PGT bNAbs. A sample is considered positive if there is a
decrease in ID50 greater than or equal to 50% for the mutant compared to the wild-type virus
[38].
For the mapping of bNAbs to the membrane-proximal external region (MPER) of gp41,
sera were tested for neutralizing activity against a chimeric HIV-2 virus containing the HIV-1
MPER region of gp41 (71312-C1) and the parenteral HIV-2 7312A clone [39].
The serum neutralizing antibodies were also mapped to the MPER region by a method
of selective peptide inhibition of neutralization [40]. gp41-specific overlapping peptides
(MPR.03: KKKNEQELLELDKWASLWNWFDITNWLWYIRKKK, 2F5.01: NEQELLELDKWASLWN,
4E10.22: CNWFDITNWLWYIRKKKand Z13e1.01: WASLWNWFDITNKKKK) were added to
the serum for 30 min at a concentration of 25 μg/ml prior to the addition of 7312A-C1
virus (HIV-2/YU2 MPER chimera). A scrambled MPER region peptide (MPR.Scr.02:
KKKRIYWLWNTIDFWNWLSAWKDLELLEQENKKK) was included as negative control. In these
assays the reduction of the neutralization activity caused by MPER derived peptides is com-
pared to that due to the mock peptide (defined as an equivalent volume of DMEM medium).
ii. ELISA analyses. ELISA assays were performed as previously described [7]. Plates were
coated with the antigen in PBS at 2 μg/ml and incubated overnight at 4˚C. The ELISA plates
were coated with the following probes:
• YU2 gp120wt and YU2 gp120 D368R protein. The mutation at position 368 reduces or
knocks out binding of most CD4bs Ab.
• The antigenically resurfaced glycoprotein RSC3 containing the CD4bs and RSC3 Δ371I/
P363N mutant, which affects the CD4 binding loop and reduces b12 and VRC01 binding.
• The RSC3 G367R probe [7,35] that creates a steric clash for mAb b12 binding but it causes
little interference with VRC01 binding.
Sera that showed a loss of reactivity to the CD4bs mutants (YU2 D368R and RSC3 Δ371I/
P363N) and reacted to YU2, RSC3 and RSC3 G367R were classified as containing CD4bs anti-
bodies as described previously [35,41]. In those samples with low reactivity to YU2 gp120wt
or/and RSC3 (endpoint titer below or equal to 2500) ELISA with RSC3 G367R probe was not
performed.
iii. Neutralization-based serum delineation analysis. Serum specificities were delineated
using a neutralization fingerprint algorithm, as described previously [42]. Briefly, a reference
set of monoclonal antibody-virus neutralization data was obtained for a set of 21 diverse HIV-
1 strains (subtypes A, B and C) against a set of representative monoclonal antibodies, divided
into epitope-specific antibody clusters (VRC01, b12, CD4, HJ16, 8ANC195, PG9, PGT128,
2G12, 2F5 and 10E8-like). For each serum, the pattern of neutralization of the same set of 21
strains was compared to the neutralization patterns (fingerprints) of the set of reference anti-
bodies, and the relative contribution of antibodies from each cluster to the neutralization by a
given serum was estimated.
Results
In order to better understand the breadth and the spectrum of neutralization against HIV-1 in
LTNP patients, we evaluated the neutralizing capacity of sera samples from the cohort of
LTNPs of the Spanish AIDS Research Network (RIS). The neutralizing activity in LTNPs was
compared with that in the control group of TPs. In these neutralization assays, neutralizing
activity of these sera were tested against a mini-panel of recombinant viruses with different
subtypes (clades and tier categorizations are given in parentheses): VI191 (A, tier 2), NL4-3 (B,
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tier 1A), 92BR025 (C, tier 1B) and CM244 (AE, tier 2) (S1 Fig) [10,43–45]. A VSV-pseudo-
typed HIV-1 was included as a control for nonspecific neutralizing activity and none of the
sera showed neutralizing activity against VSV-pseudotyped HIV-1. We considered that a
serum sample displayed broadly neutralizing activity (bNA) when it was capable of neutraliz-
ing all the recombinant viruses tested across with a titre200, with no neutralization of the
VSV-pseudotyped control.
LTNP serum samples capable to neutralize all the viruses in the mini-panel with an
ID50200 were selected and these samples were screened against an extended panel of 10
viruses more with various subtypes (Fig 1).
The percentage of individuals with broad neutralizing responses found among LTNPs was
9.3% (12/129) and in TPs was 18.8% (33/176).
Although the number of broad neutralizer individuals in the viremic population was higher,
broad neutralizer patients were also found among the elite controllers. Six of the LTNPs with
bNA had viral loads under 50 copies/ml indicating that patients with undetectable viral loads
are capable to develop a broadly neutralizing response. These six individuals represent 7% of
the elite controllers´ population (6/87) while in the case of the viremic LTNPs the ratio of indi-
viduals with bNA was 14% (6/42) (Table 1).
The epitopes for the binding of the neutralizing antibodies contained in LTNPs sera and in
TPs sera from patients with a broad neutralization profile were mapped.
NAbs directed to the CD4bs were identified with ELISA techniques. A serum was consid-
ered positive if there was a 5-fold or greater difference in serum binding to the wild type com-
pared to the corresponding CD4bs knockout mutant probe and if it showed a good reactivity
to YU2 gp120wt or/and RSC3 (endpoint titer above 2500). Sera with NAbs to the CD4bs were
detected in several samples of LTNPs (597473, 3227057, 2090945 and 449326) and also in TPs
(670–002, 521–006, 282–046, 363–014, 651–003, 308–040, 661–002, 328–017, 380–017, 530–
013, 390–012, 706–000, 738–000, 97–031, 53–036, 642–007) (Table 3).
To determine whether the CD4bs antibodies contained in sera were responsible for broad
neutralization, neutralization competition assays using RSC3 glycoprotein containing the
CD4bs were performed (Fig 2). RSC3 addition inhibited neutralization mediated by two sam-
ples of sera from LTNPs (449326 and 597473). For sample 449326 RSC3 addition inhibited
Fig 1. Serum neutralization data (ID50s) for LTNPs capable of neutralizing all the viruses from the mini-panel. Selected sera samples from the
LTNP cohort capable to neutralize (ID50200) the mini-panel of 4 viruses (NL4-3, VI191, 92BR025 and CM244) were screened for neutralization
against 10 more viruses. Viruses of the minipanel are shaded grey. Median viral loads for the previous five years to the serum sample are shown. In the
last column the percentage of neutralized viruses is shown. No significant neutralization of the VSV pseudotyped virus was observed in any of the
samples. Reciprocal serum ID50 values200 and<400 are highlighted in yellow,400 and<1000 in orange and1000 in red.
https://doi.org/10.1371/journal.pone.0193773.g001
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Table 3. Serum endpoint titers in ELISAs to determine the presence of CD4bs antibodies.
Subject YU2 core YU2 D368R Ratioa RSC3 RSC3 Δ371I/P363N Ratioa RSC3 G367R RSC3 Δ371I/P363N Ratioa
LTNPs
ECs
2197004 62500 2500 25 2500 2500 1 2500 2500 1
582150 2500 2500 1 2500 100 25 nd 100 nd
597473 312500 12500 25 312500 500 625 1562500 500 3125
125966 312500 62500 5 12500 2500 5 2500 2500 1
2060579 62500 12500 5 100 100 1 nd 100 nd
20172839 12500 2500 5 2500 100 25 100 100 1
VCs
3227057 312500 12500 25 62500 500 125 2500 500 5
2062035 1562500 62500 25 312500 12500 25 12500 12500 1
2090945 62500 12500 5 12500 500 25 2500 500 5
449326 312500 12500 25 1562500 12500 125 62500 12500 5
121875 62500 12500 5 62500 12500 5 12500 12500 1
6302555 62500 12500 5 100 500 0,2 nd 500 nd
TPs
359–016 nd nd 2500 100 25 100 100 1
734–000 62500 12500 5 2500 2500 1 nd 2500 nd
670–002 nd nd 12500 2500 5 12500 2500 5
521–006 312500 12500 25 62500 2500 25 12500 2500 5
600–003 312500 312500 1 312500 62500 5 312500 62500 5
344–017 nd nd 2500 500 5 2500 500 5
72–071 nd nd 2500 100 25 2500 2500 1
339–017 nd nd 2500 2500 1 2500 2500 1
269–049 nd nd 12500 500 25 500 500 1
378–017 nd nd 500 100 5 500 100 5
282–046 nd nd 12500 100 125 12500 100 125
322–012 nd nd 12500 500 25 500 500 1
363–014 312500 62500 5 12500 2500 5 62500 2500 25
651–003 nd nd 12500 500 25 2500 500 5
701–000 nd nd 2500 2500 1 2500 2500 1
308–040 312500 12500 25 1562500 500 3125 2500 500 5
661–002 nd nd 12500 100 125 500 100 5
56–024 nd nd 2500 500 5 500 500 1
139–020 nd nd 500 100 5 100 100 1
328–017 nd nd 2500 500 5 2500 500 5
380–017 nd nd 12500 2500 5 12500 2500 5
629–005 nd nd 500 500 1 500 500 1
530–013 nd nd 312500 500 625 12500 500 25
390–012 nd nd 12500 500 25 2500 500 5
706–000 nd nd 62500 100 625 12500 100 125
528–006 312500 62500 5 62500 2500 25 2500 2500 1
622–005 nd nd 500 100 5 500 100 5
738–000 nd nd 12500 500 25 12500 500 25
97–031 nd nd 62500 12500 5 62500 12500 5
708–002 nd nd 2500 100 25 500 100 5
376–036 nd nd 2500 500 5 2500 500 5
(Continued)
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neutralization of RW020 (35.2%) and ZA012 (35.1%). For serum 597473 there was a 56%
reduction in neutralization of ZA012 strain attributed to RSC3.
For the mapping of V1V2 and V3 glycan-dependent HIV-1 NAbs (Fig 3 and S2 Fig), neu-
tralization assays in TZM-bl using JRCSF.N160K and JRCSF.N332A respectively were per-
formed. A decrease of 2 fold or more in serum neutralization against JRCSF.N160K or JRCSF.
N332A compared to the neutralization of wild-type JRCSF indicates the presence of neutraliz-
ing antibodies directed to glycans in V1V2 or V3, respectively. From the results obtained it can
be deduced that glycan-dependent HIV-1 NAbs are significantly more abundant in the sam-
ples from LTNPs (11/12) than in those from TPs (12/33) (p value = 0.0017, Fisher’s exact test).
Sera were analyzed to detect antibodies directed against MPER region of gp41 (Fig 4 and S3
Fig) assessing neutralizing activity against 7312A and 7312A-C1 viruses and anti-MPER anti-
bodies were detected in both groups of patients. To confirm the presence of MPER neutraliz-
ing antibodies in the sera, the specificity of the antibodies against MPER was inhibited with
soluble peptides containing different fragments of this region (Table 4). Four serum samples
Table 3. (Continued)
Subject YU2 core YU2 D368R Ratioa RSC3 RSC3 Δ371I/P363N Ratioa RSC3 G367R RSC3 Δ371I/P363N Ratioa
53–036 nd nd 12500 500 25 2500 500 5
642–007 312500 2500 125 1562500 2500 625 62500 2500 25
nd: not determined; ECs: Elite controllers; VCs: Viremic controllers; TPs: Typical progressors
aRatio of previous two endpoint titers. Sera with a ratio RSC3 Δ371I/P363N and a loss of activity on the cognate CD4bs mutant greater than or equal to 5-fold are
considered reactive and bolded.
https://doi.org/10.1371/journal.pone.0193773.t003
Fig 2. CD4 binding site neutralizing antibody specificity. Sera that were ELISA reactive with resurfaced stabilized
cores RSC3 and RSC3 G367R, were assayed for inhibition of neutralization using RSC3 and RSC3 P363N as inhibitors.
The net percent reduction in neutralization of JRFL, RW020 or ZA012 attributed to RSC3 compared to RSC3 P363N is
plotted (y axis). Each serum is represented by a different symbol. The color of the symbol depends on the virus used in
the neutralization assay. A reduction greater than 30% is considered positive. RSC3 addition inhibited neutralization
mediated by 2 sera from LTNPs (449326 and 597473) and no serum of typical progressors.
https://doi.org/10.1371/journal.pone.0193773.g002
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from LTNPs and eight serum samples from TPs competed with the MPR.03 peptide that cov-
ers the complete MPER domain. One of the LTNP samples (2090945) contained antibodies
similar to 4E10. One serum sample from TPs (53–036) contained bNAbs directed against the
same epitope than Z13 and five TP samples (600–003, 701–000, 390–012, 622–005 and 642–
007) contained bNAbs directed against the same epitope than 4E10. The epitope of one TP
sample (56–024) overlapped that of both 4E10 and 2F5 and the epitope of other TP sample
(661–002) overlapped that of 4E10 and Z13e1.
In summary, we found that most of the bNAbs from LTNPs map known neutralization epi-
topes and that in some subjects the neutralization breadth is mediated by antibodies with dif-
ferent specificities (Figs 5 and 6). A summary of serum neutralization specificities found with
standard mapping is shown (Fig 5).
It has been shown that similarity in neutralization fingerprint correlates with similarity in
epitope [42]. Therefore, epitope specificities of HIV-1–neutralizing antibodies in serum were
Fig 3. Detection of glycan-dependent HIV-1 neutralizing antibodies in sera from LTNPs and typical progressors. Sera with V1V2 and V3 glycan-
dependent HIV-1 NAbs are detected by neutralization assays with the parental JRCSF and the corresponding N160K and N332A mutants (V1V2 and
V3 respectively). Sera with reactivity to glycan-dependent motives in V2 and V3 are indicated in orange and blue respectively. Percent serum
neutralizing activity sensitive to the indicated residue replacement was calculated using the equation [1 − (ID50 mutant/ID50 wild type)] x 100. A
sample is considered positive if there is a decrease in ID50 greater than or equal to 50% for the mutant relative to the wild-type virus. Monoclonal
antibodies 2G12 and PG9 have been used as controls and are indicated by a black box. SEMs of two independent assays are shown. In this figure only
samples with neutralizing antibodies directed to glycans in V1V2 and/or V3 are shown.
https://doi.org/10.1371/journal.pone.0193773.g003
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elucidated from the serum pattern of neutralization against a panel of 21 HIV-1 isolates. The
patterns of neutralization of the sera were compared with a reference set of 10 epitope-specific
neutralization fingerprints (one for each epitope-specific antibody cluster). The predicted
prevalence of the different clusters is shown as a heat map for each serum (Fig 6A). These data
exhibited a high concordance with the ones obtained using the experimental assays (Fig 5),
with at least one of the top two neutralization-based specificities identified by standard map-
ping in 92% of the sera (Fig 6B). Epitopes involved in bNAbs-mediated protection have been
characterized by these different approaches and activity against all the analyzed epitopes was
displayed in LTNPs and TPs (Fig 6C).
Discussion
It has been suggested that in HIV-infected individuals high levels of viral replication and the
time since infection correlates with the induction of bNAbs [1,21,46]. However, in this work
we have detected broadly neutralizing antibodies against HIV-1 in a cohort of LTNPs with low
Fig 4. Detection of antibodies specific for the membrane-proximal region in the sera from LTNPs and typical progressors. For the mapping of
anti-MPER neutralizing antibodies, the serum samples were tested against the parental HIV-2 isolate 7312A and the 7312A chimera containing HIV-1
MPER fragments (7312A-C1). Monoclonal antibodies 2F5 and 4E10 have been used as controls and are indicated by a black box. In this figure only
samples with anti-MPER neutralizing antibodies are shown.
https://doi.org/10.1371/journal.pone.0193773.g004
Characterization of bNAbs to HIV-1 in LTNPs
PLOS ONE | https://doi.org/10.1371/journal.pone.0193773 March 20, 2018 10 / 18
or undetectable levels of viremia. Actually, LTNP were classified in two sub-groups according
to viremia levels: elite controllers (persistent undetectable viremia) and viremic controllers
(VL<10.000 copies/ml). Although we have found a higher percentage of individuals with
bNAbs in viremic controllers (14% vs 7%), bNAbs were also found in long-term elite control-
lers, suggesting that other factors besides persistently detected viremia could drive the develop-
ment of bNAbs. However, we cannot exclude that this broad humoral immune response
could be due to hidden viral replication in other tissues such as gut-associated lymphoid tissue
(GALT) or tonsils.
LTNPs and TPs developed antibodies against all kinds of epitopes analyzed. Therefore,
bNAbs in LTNPs are mapped to specific known neutralization epitopes. These data have been
obtained using two different approaches, neutralization-based and standard serum mapping.
The concordance between these two methods was high. These two approaches have been pre-
viously compared in a population of 21 sera [42]. The data obtained in the present study of 19
additional sera validate the previous reports of concordance between neutralization finger-
printing and standard serum mapping, further underlining the utility of the neutralization-
based serum-epitope predictions.
Only two of the sera with binding antibodies against the CD4bs detected by ELISA had
detectable neutralization activity confirmed by RSC3 competition neutralization assays. One
possible explanation is that if the virus is neutralized by antibodies directed against other epi-
tope, there will not be an effect on neutralization reduction mediated by RSC3. The sera sam-
ples with no inhibition in neutralization by this glycoprotein could have few antibodies against
CD4bs or antibodies with low affinity incapable of mediating neutralization, only detectable
Table 4. ID50 titers in the absence and the presence of MPER-derived peptides.
Serum ID50 % Neutralization inhibited by peptide
Mock MPR.Scr.02 MPR.03 2F5.01 4E10.22 z13e1.01 MPR.Scr.02 MPR.03 2F5.01 4E10.22 z13e1.01
LTNPs
ECs
597473 580 541 365 533 711 423 7 37 8 0 27
125966 85 100 92 89 117 103 0 0 0 0 0
20172839 241 126 37 210 128 111 48 84 13 47 54
VCs
3227057 129 123 61 98 113 91 5 52 24 12 29
2062035 357 425 162 511 380 470 0 55 0 0 0
2090945 111 134 27 90 38 118 0 75 19 66 0
TPs
600–003 4047 5444 12 5823 10 2563 0 100 0 100 37
651–003 797 371 345 548 647 327 53 57 31 19 59
701–000 2779 1521 227 1284 677 1447 45 92 54 76 48
661–002 2244 2236 771 1730 973 853 0 66 23 57 62
56–024 3279 3216 94 1336 146 7461 2 97 59 96 0
390–012 1494 1306 712 1806 591 856 13 52 0 60 43
706–000 1539 896 2313 876 993 814 42 0 43 35 47
622–005 773 1014 170 407 82 390 0 78 47 89 50
53–036 164 121 46 119 135 46 26 72 27 18 72
642–007 5932 8449 588 8646 375 4900 0 90 0 94 17
Indicator of peptide-specific neutralizing antibody response, calculated as (1 –ID50 with peptide/ID50 with mock peptide) x 100. Values higher than 50% are shown in
bold
https://doi.org/10.1371/journal.pone.0193773.t004
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Fig 5. Summary of experimental serum mapping of HIV-1 sera from LTNPs and TPs with a broad neutralization
profile. Data obtained from the assays used to map CD4bs, V1V2 glycans, V3 glycans and MPER regions are shown.
Epitope groups are marked with a plus sign (+) if predicted by the mapping assays to be present in a given serum.
https://doi.org/10.1371/journal.pone.0193773.g005
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by ELISA techniques. Then, in these sera the neutralization may be due mainly to the presence
of high-affinity antibodies against other domains.
When we analyzed the sera samples with the standard serum mapping, we observed that V3
glycan-dependent HIV-1 NAbs were more abundant in LTNPs (11/12) than in TPs (12/33).
This prevalence of the V3 glycan-dependent NAbs in LTNPs was also detected with the neu-
tralization-based analysis. A previous study has also found high levels of 2G12-like antibodies
in broadly neutralizing samples from LTNPs [47]. A question that arises from these results is
whether these antibodies are contributing to the control of viremia in LTNP. The V3 region is
known to be highly immunogenic and individuals develop antibodies directed against the
C3-V4 region early in infection [48,49]. HIV overcomes the response through mutation but
this variability is decreased in the low viral rates of replication. It could be possible that in
some LTNPs bNAbs contribute to viral control. Actually it has been recently described that
Abs from one EC patient can exhibit autologous neutralization and these antibodies are con-
tributing to elite control in this individual [22]. To address this hypothesis autologous neutrali-
zation should be detected in LTNP patients but due to extremely low viral loads, viral isolation
and cloning of the envelope is unfeasible in the majority of patients.
Fig 6. Delineation of serum specificities in HIV-1 sera from LTNPs and TPs with a broad neutralization profile. (A) Predictions
based on the serum neutralization pattern against a panel of diverse HIV-1 isolates are shown on the left of the figure. For each
serum the predicted relative prevalence of each reference antibody cluster is presented as a heat map where stronger neutralization
signals by the antibody cluster are shown as darker colors (higher fractional numbers). Breadth was measured as the percentage of
viruses neutralized with an ID50>50 and potency as the geometric mean ID50 titers of sera. Sera with breadth less than 20% are
greyed out since the computational predictions in those cases are less reliable (B) Concordance between neutralization-based and
standard serum mapping. Sera with breadth less than 20% were excluded. The agreement between the two methods was good. In
92% of the sera at least one of top two computational neutralization-based predictions was identified by standard mapping. (C)
Frequency of the epitope specificities of HIV-1 neutralizing antibodies in the sera from LTNPs and TPs with broadly neutralizing
activity. Sera with breadth less than 20% were excluded.
https://doi.org/10.1371/journal.pone.0193773.g006
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In some subjects neutralization breadth was mediated by more than one antibody epitope
specificity which is in agreement with previous observations showing that broadly neutralizing
activity of some HIV-1 infected individuals is due to antibodies that target more than one epi-
tope [38,50–52].
bNAbs require a large number of somatic mutations [7] that are related with preservation
of T follicular helper cells (TFH). HIV infected individuals have several defects in the humoral
immune system, including B cell abnormalities associated with HIV replication-induced
immune cell activation and TFH priming [53–55]. Elite controllers with viral load consistently
below 50 copies/ml could develop a robust response mediated by their well-preserved B cells
generating high affinity antibodies. Therefore control of the viral load could be associated to
an improved maturation of antibodies in the affinity for the antigen. TFH are involved in the
development of these antibodies as B cell memory maturation and generation of high-affinity
neutralizing antibodies is dependent on extensive signaling from TFH cells [56]. However, in
productive HIV infection, high levels of HIV viremia drive the expansion of TFH cells which
is associated with perturbation of the B cell compartment, resulting in deregulated antibody
production [57,58]. One potential hypothesis could point to a better preserved B cell function
in LTNPs including appropriate regulation of TFH resulting in a generation of bNAbs with
high levels of somatic hypermutation despite lower levels of antigen.
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